RNA-seq analysis in breast cancer cell lines BT549 WT and SF3A3 5'UTR DSL3 edited.
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA636284 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR11888094.fastq.gz | Fastqsanger.gz | |||
| SRR11888095.fastq.gz | Fastqsanger.gz | |||
| SRR11888096.fastq.gz | Fastqsanger.gz | |||
| SRR11888097.fastq.gz | Fastqsanger.gz | |||
| SRR11888098.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 6 |
Similar Datasets
Project description:Splicing is a central RNA-based process commonly altered in human cancers; however, how the splicing machinery is co-opted during tumorigenesis remains largely unresolved. Here we identify the splice factor SF3A3 at the nexus of an oncogenic translation program that rewires splicing to promote tumorigenesis. Our results suggest that key spliceosomal networks centered on the essential core U2-associated factor, SF3A3, are exquisitely controlled at the translation level during oncogenic stress. Upon oncogene activation, SF3A3 translation is rapidly enabled via a conserved internal stem-loop structure embedded in the transcript 5’ untranslated region (UTR). Uncoupled SF3A3 translation leads to alternative splicing of several mRNAs involved in mitochondrial dynamics, and induces a metabolic switch that fuels cancer initiation properties in MYC-driven breast tumorigenesis in vivo. Finally, we compelling show that SF3A3 is post-transcriptionally altered and predicts for poor prognosis in aggressive triple negative breast cancers. Together, these findings unveil a highly dynamic regulatory network that interfaces mRNA splicing and translation to orchestrate cancer gene expression networks.
2021-03-25 | GSE151529 | GEO
Project description:To delineate the native structure of SF3A3 5'UTR, RNA was harvested from IMR90 human fibroblasts. Using specific primers and DMS-MaPSeq pipeline, we validated individual base pairing probabilities within the endogenous 5'UTR of SF3A3 (samples described as 'in vivo' transcribed). DMS-MaP-Seq is based on the principle that DMS is highly reactive to solvent-accessible, unpaired adenine (A) and cytosine (C) residues, but remains inert toward base-paired A and C engaged in Watson-Crick interactions (Rouskin et al., 2014). Using this methodology, we identify stable stem-loop structure (SL3) positioned within SF3A3 5'UTR. To further validate the functional importance of SL3, the structural point mutant (SF3A3 5'UTR mut: A55C and U95A) and rescue (SF3A3 5'UTR res: A55C and U95A and rescuing point mutations G61U and U100G) sequences of SF3A3 5'UTR were cloned into the reporter plasmid. For the validation of these mutate-and-rescue constructs, plasmids were in vitro transcribed and either used directly (samples described as 'in vitro') for DMS-MaP-Seq probing.
2021-03-25 | GSE147504 | GEO
Project description:Targeted DMS probing of SF3A3 5' UTR
| PRJNA615008 | ENA
Project description:Splicing is a central RNA-based process commonly altered in human cancers; however, how the splicing machinery is co-opted during tumorigenesis remains largely unresolved. Here we identify the splice factor SF3A3 at the nexus of an oncogenic translation program that rewires splicing to promote tumorigenesis. Our results suggest that key spliceosomal networks centered on the essential core U2-associated factor, SF3A3, are exquisitely controlled at the translation level during oncogenic stress. Upon oncogene activation, SF3A3 translation is rapidly enabled via a conserved internal stem-loop structure embedded in the transcript 5’ untranslated region (UTR). Uncoupled SF3A3 translation leads to alternative splicing of several mRNAs involved in mitochondrial dynamics, and induces a metabolic switch that fuels cancer initiation properties in MYC-driven breast tumorigenesis in vivo. Finally, we compelling show that SF3A3 is post-transcriptionally altered and predicts for poor prognosis in aggressive triple negative breast cancers. Together, these findings unveil a highly dynamic regulatory network that interfaces mRNA splicing and translation to orchestrate cancer gene expression networks.
2021-03-25 | GSE147505 | GEO
Project description:We identified the SOX4 transcription factor and integrin alpha V encoded by the ITGAV gene as important resistance mechanisms to T cell-mediated cytotoxicity of TNBC cells. Here, we performed RNA seq. analysis of SOX4 and ITGAV deficient (CRISPR knockout) BT549 human and 4T1 murine TNBC cells as compared to control edited counterparts. Additionally, we performed SOX4 specific ChIP-seq studies in BT549 human TNBC cells. The objective of the study was to identify the molecular regulators and signaling pathways that mediate resistance to T cell mediated immunity. GSEA analysis of RNA-seq data showed that the 'interferon response' represented one of the top pathways for genes upregulated in SOX4 or ITGAV edited compared to control TNBC cells. In contrast, gene sets associated with TGF beta and TNF alpha/NF kappa b were negatively enriched in both Sox4 and Itgav edited TNBC cells. Further analysis of RNA-seq data showed that SOX4 or ITGAV edited TNBC cells contained higher mRNA levels of many interferon-stimulated genes (ISGs), including genes associated with important innate immune pathways such as RIG-I/MDA-5, cGAS - STING and the AIM2 inflammasome
2021-01-01 | GSE144012 | GEO
Project description:LncRNA SNHG15 is an oncogenic lncRNA in a variety of cancers including breast cancer, lung cancer, and hepatocellular carcinoma. To screen genes regulated by SNHG15, we performed RNA-seq with stable SNHG15-overexpression BT549 cells, using BT549-pcIP2 as control.
2023-06-08 | GSE220492 | GEO
Project description:Aberrant expression of splicing factors is increasingly recognized as a critical driver of cancer progression. Herein, we unravel SF3A3, a core component of the spliceosome, being highly expressed in endometrial cancer (EC) and playing an oncogenic role by driving splicing alterations, and consequently promoting tumor progression and therapeutic resistance. Mechanistically, We found through RIP seq data that SF3A3 could specifically bind to a series of genes, including c-FOS. Subsequent experiments have confirmed that SF3A3 coud regulate the alternative splicing of c-FOS, an anti-apoptotic gene implicated in resistance to cisplatin, a first-line chemotherapeutic agent for EC. SF3A3 facilitates the inclusion of exons 2 and 3 in c-FOS, resulting in the production of full-length c-FOS, which promotes tumor progression and cisplatin resistance.
2025-11-14 | GSE287381 | GEO
Project description:To explore the DEGs in BT549 cell line treated with ENL.
2024-12-23 | GSE272946 | GEO
Project description:Transcriptional profiling with samples from BT549 cells that were infected with control or NFIL3 shRNA
2012-09-02 | GSE31425 | GEO
Project description:We performed microarray analysis on BT549 cells that express miR-200c in a doxycycline (dox)-inducible manner from the miR-200c-TripZ system.
2017-12-20 | GSE108271 | GEO